Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec;22(12):1652-1654.
doi: 10.1016/S1473-3099(22)00517-5. Epub 2022 Sep 5.

Evaluating novel COVID-19 vaccines in the current chapter of the pandemic

Corine H GeurtsvanKessel  1 , Rory D de Vries  2
Affiliations
Comment

Evaluating novel COVID-19 vaccines in the current chapter of the pandemic

Corine H GeurtsvanKessel et al. Lancet Infect Dis. 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. We thank Marion Koopmans for a critical review of the manuscript.

Comment on

References

    1. Lazarus R, Querton B, Corbic Ramljak I, et al. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect Dis. 2022 doi: 10.1016/S1473-3099(22)00502-3. published online Sept 5. - DOI - PMC - PubMed
    1. Petrović V, Vuković V, Patić A, Marković M, Ristić M. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection—a comparative study from Novi Sad, Serbia. PLoS One. 2022;17:e0263468. - PMC - PubMed
    1. Singh AK, Phatak SR, Singh R, et al. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) among health care workers in India: the final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine. 2021;39:6492–6509. - PMC - PubMed
    1. GeurtsvanKessel CH, Geers D, Schmitz KS, et al. Divergent SARS-CoV-2 omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7:eabo2202. - PMC - PubMed
    1. Mykytyn AZ, Rissmann M, Kok A, et al. Antigenic cartography of SARS-CoV-2 reveals that omicron BA.1 and BA.2 are antigenically distinct. Sci Immunol. 2022 doi: 10.1126/sciimmunol.abq4450. published online June 23. - DOI - PMC - PubMed